Tectonic Therapeutic ( (TECX) ) has issued an announcement.
Tectonic Therapeutic, Inc. has reported positive results from their Phase 1a clinical trial for TX45, a potential treatment for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). TX45, which targets G-protein coupled receptors, was well-tolerated and demonstrated a favorable safety and pharmacokinetic/pharmacodynamic profile, enabling the selection of doses for an upcoming Phase 2 clinical trial. The company is also progressing with another trial aimed at observing TX45’s acute hemodynamic effects, with topline results expected in the second quarter of 2025. There are currently no approved treatments for the Group 2 PH population with HFpEF, indicating a significant market need that TX45 could potentially address.
For detailed information about TECX stock, go to TipRanks’ Stock Analysis page.
